Aberrant de novo cholesterogenesis: Clinical significance and implications

Rida Rashid, Fatima Ameer, Hubert Kalbacher, Lisa Scandiuzzi, Nousheen Zaidi

Research output: Contribution to journalArticle

Abstract

Human cells can acquire cholesterol from the circulation but also have the ability to synthesize it via de novo cholesterogenesis (DC). Cholesterol absorption and de novo cholesterogenesis are the key processes that modulate cholesterol homeostasis in the human body. The endogenous biosynthesis of cholesterol substantially contributes to the whole-body cholesterol pool. Additionally, dysregulation of this pathway is associated with diverse medical conditions. The present review focuses on our current understanding of the cholesterogenic pathway and the various different factors regulating this pathway. It also highlights dysregulation of this pathway in various physiological and pathological conditions including cardiovascular diseases, type II diabetes, obesity and viral infections.

Original languageEnglish (US)
Pages (from-to)356-361
Number of pages6
JournalClinica Chimica Acta
Volume450
DOIs
Publication statusPublished - Oct 23 2015
Externally publishedYes

    Fingerprint

Keywords

  • Cholesterol absorption
  • De novo cholesterol synthesis
  • Mevalonate pathway

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Rashid, R., Ameer, F., Kalbacher, H., Scandiuzzi, L., & Zaidi, N. (2015). Aberrant de novo cholesterogenesis: Clinical significance and implications. Clinica Chimica Acta, 450, 356-361. https://doi.org/10.1016/j.cca.2015.09.014